大环内酯类抗生素耐药儿童肺炎支原体感染药物治疗进展  

Progress in drug treatment of macrolide resistant Mycoplasma pneumoniae infection in children

作　　者：李威[1] 谢晓恬[1] LI Wei;XIE Xiaotian(Department of Pediatrics,Tongji Hospital of Tongji University,Shanghai 200065,China)

机构地区：[1]同济大学附属同济医院儿科,上海200065

出　　处：《世界临床药物》2021年第12期1049-1055,共7页World Clinical Drug

摘　　要：肺炎支原体肺炎(Mycoplasma pneumoniae pneumonia,MPP)是儿童社区获得性肺炎(community acquired pneumonia,CAP)最常见的类型之一。近年来,大环内酯类耐药肺炎支原体(macrolide resistant Mycoplasma pneumoniae,MRMP)感染以及其所致的难治性MPP(refractory Mycoplasma pneumoniae pneumonia,RMPP)及重症MPP发生率均逐渐增高,已成为儿科临床重点关注及研究的热点。现复习了近年来国外文献,结合我国相关专家共识,简要归纳了儿童MPP的规范诊治原则,尤其是MRMP相关基础与临床研究进展,以期为临床诊治提供一定参考。Mycoplasma pneumoniae pneumonia(MPP)is one of the most common types of community acquired pneumonia(CAP)in children.In recent years,the incidence of macrolide resistant Mycoplasma pneumoniae(MRMP)infection,refractory Mycoplasma pneumoniae(RMPP)and severe MPP has gradually increased,which has become an important clinical concern and research hotspot in pediatrics.This paper reviewed the international literature in recent years,combined with the consensus of relevant experts in China,briefly summarizes the standardized diagnosis and treatment principles of MPP in children,especially the basic and clinical research progress of MRMP,in order to provide some reference for clinical diagnosis and treatment.

关 键 词：社区获得性肺炎 肺炎支原体肺炎 发病机制 抗生素耐药 

分 类 号：R725.6[医药卫生—儿科] R978.1[医药卫生—临床医学]